| German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients K Rahbar, H Ahmadzadehfar, C Kratochwil, U Haberkorn, M Schäfers, ... Journal of Nuclear Medicine 58 (1), 85-90, 2017 | 867 | 2017 |
| Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation B Sangro, L Carpanese, R Cianni, R Golfieri, D Gasparini, S Ezziddin, ... Hepatology 54 (3), 868-878, 2011 | 704 | 2011 |
| Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study H Ahmadzadehfar, K Rahbar, S Kürpig, M Bögemann, M Claesener, ... EJNMMI research 5, 1-8, 2015 | 337 | 2015 |
| Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer H Ahmadzadehfar, E Eppard, S Kürpig, R Fimmers, A Yordanova, ... Oncotarget 7 (11), 12477, 2016 | 296 | 2016 |
| Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis K Rahbar, M Schmidt, A Heinzel, E Eppard, A Bode, A Yordanova, ... Journal of Nuclear Medicine 57 (9), 1334-1338, 2016 | 251 | 2016 |
| Theranostics in nuclear medicine practice A Yordanova, E Eppard, S Kürpig, RA Bundschuh, S Schönberger, ... OncoTargets and therapy, 4821-4828, 2017 | 234 | 2017 |
| Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients H Palmedo, C Marx, A Ebert, B Kreft, Y Ko, A Türler, R Vorreuther, ... European journal of nuclear medicine and molecular imaging 41, 59-67, 2014 | 212 | 2014 |
| Radioembolization of liver tumors with yttrium-90 microspheres H Ahmadzadehfar, HJ Biersack, S Ezziddin Seminars in nuclear medicine 40 (2), 105-121, 2010 | 191 | 2010 |
| PSMA theranostics: current status and future directions K Rahbar, A Afshar-Oromieh, H Jadvar, H Ahmadzadehfar Molecular imaging 17, 1536012118776068, 2018 | 189 | 2018 |
| Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate S Ezziddin, M Attassi, CJ Yong-Hing, H Ahmadzadehfar, W Willinek, ... Journal of nuclear medicine 55 (2), 183-190, 2014 | 189 | 2014 |
| Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 H Ahmadzadehfar, S Wegen, A Yordanova, R Fimmers, S Kürpig, ... European journal of nuclear medicine and molecular imaging 44, 1448-1454, 2017 | 175 | 2017 |
| Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate A Sabet, K Ezziddin, UF Pape, H Ahmadzadehfar, K Mayer, T Pöppel, ... Journal of Nuclear Medicine 54 (11), 1857-1861, 2013 | 161 | 2013 |
| The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment H Ahmadzadehfar, A Sabet, K Biermann, M Muckle, H Brockmann, C Kuhl, ... Journal of Nuclear Medicine 51 (8), 1206-1212, 2010 | 159 | 2010 |
| PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall … K Rahbar, M Boegemann, A Yordanova, M Eveslage, M Schäfers, ... European journal of nuclear medicine and molecular imaging 45, 12-19, 2018 | 152 | 2018 |
| Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study EA Carlsen, N Fazio, D Granberg, S Grozinsky-Glasberg, ... Endocrine-related cancer 26 (2), 227-239, 2019 | 151 | 2019 |
| The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer A Yordanova, A Becker, E Eppard, S Kürpig, C Fisang, G Feldmann, ... European Journal of Nuclear Medicine and Molecular Imaging 44, 1473-1479, 2017 | 126 | 2017 |
| Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617 J Ferdinandus, E Eppard, FC Gaertner, S Kürpig, R Fimmers, ... Journal of Nuclear Medicine 58 (2), 312-319, 2017 | 121 | 2017 |
| Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma R Golfieri, JI Bilbao, L Carpanese, R Cianni, D Gasparini, S Ezziddin, ... Journal of hepatology 59 (4), 753-761, 2013 | 117 | 2013 |
| Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours A Sabet, T Haslerud, UF Pape, A Sabet, H Ahmadzadehfar, F Grünwald, ... European journal of nuclear medicine and molecular imaging 41, 205-210, 2014 | 111 | 2014 |
| Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors S Ezziddin, T Logvinski, C Yong-Hing, H Ahmadzadehfar, HP Fischer, ... Journal of Nuclear Medicine 47 (2), 223-233, 2006 | 109 | 2006 |
PD Dr. med. Anna YordanovaDepartment of Nuclear Medicine, Klinikum Westfalen Dortmund在 mail.de 的电子邮件经过验证
